Skip to main content

Advertisement

SpringerLink
Log in

Une névrite optique toxique induite par le sunitinib

Optic neuritis associated with sunitinib

  • Cas clinique/Case report
  • Published:
Oncologie

Abstract

Antiangiogenic therapies have an increasing place in oncology. The frequency of their use leads the occurring of underestimated, particularly, neurological, adverse effects. We report a case of optic neuritis attributed to the treatment by sunitinib in a patient with renal cancer.

Résumé

Les traitements antiangiogéniques occupent une place croissante en oncologie. La fréquence de leur utilisation induit l’apparition d’effets secondaires jusqu’alors sous-estimés, notamment neurologiques. Nous rapportons un cas de névrite optique attribuée au traitement par sunitinib chez une patiente atteinte d’un cancer du rein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Allen JA, Adlakha A, Bergethon PR (2006) Reversible posterior leukoencephalopathy syndrom after bevacizumab-Folfiri regimen for metastatic colon cancer. Arch Neurol 63: 1475–1478

    Article  PubMed  Google Scholar 

  2. Cumurciuc R, Martinez-Almoyna L, Henry C, et al. (2008) Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris) 164: 605–607

    Article  CAS  Google Scholar 

  3. Fraunfelder FW, Solomon J, Druker BJ, et al. (2003) Ocular side-effects associated with imatinib mesylate (Gleevec®). J Ocul Pharmacol Ther 19: 371–375

    Article  PubMed  CAS  Google Scholar 

  4. Govind Babu K, Attili VS, Bapsy PP, et al. (2007) Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 27: 43–44

    Article  PubMed  CAS  Google Scholar 

  5. Martín G, Bellido L, Cruz JJ (2007) Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25: 3559

    Article  PubMed  Google Scholar 

  6. Medioni J, Cojocarasu O, Banu E, et al. (2007) Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol 2: 193–195

    Article  Google Scholar 

  7. Van der Veldt AA, Van den Eertwegh AJ, Hoekman K, et al. (2007) Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol 18: 1747–1750

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie, centre hospitalier de la région d’Annecy, 1, avenue de l’Hôpital, BP 90074, F-74374, Pringy cedex, France

    M. -E. Deschamps

  2. Service d’oncologie, centre hospitalier de Chambéry, 7, square Massalaz, BP 1125, F-73011, Chambéry cedex, France

    J. Provencal

Authors
  1. M. -E. Deschamps
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Provencal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. -E. Deschamps.

About this article

Cite this article

Deschamps, M.E., Provencal, J. Une névrite optique toxique induite par le sunitinib. Oncologie 14, 679–681 (2012). https://doi.org/10.1007/s10269-012-2148-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-012-2148-7

Keywords

Mots clés

Search

Navigation